Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients With Refractory Multiple Myeloma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-0221-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

Clinical Genitourinary Cancer
OncologyUrology
2013English

Small Molecule Receptor Tyrosine Kinase Inhibitor of Platelet-Derived Growth Factor Signaling (SU9518) Modifies Radiation Response in Fibroblasts and Endothelial Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Inhibition of Chronic and Acute Skin Inflammation by Treatment With a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal of Pathology
Forensic MedicinePathology
2008English

Sorafenib, a Dual Raf Kinase/Vascular Endothelial Growth Factor Receptor Inhibitor Has Significant Anti-Myeloma Activity and Synergizes With Common Anti-Myeloma Drugs

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research
Cancer ResearchOncology
2008English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Increased Risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy